Erythema Multiforme Major Associated With Community-Acquired Pneumonia: Lessons From a Case Report

Introduction

Erythema multiforme (EM) is an acute immune-mediated inflammatory mucinous skin condition characterized by urticarial papules, red spots, plaques, bilateral iris's vesicles target, or limb distribution iris (1). This condition is often confused with more serious conditions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN). Bastrop-Garin et al. were first to report EM based on its morbid physiology, etiology, and clinical processes (2, 3). EM is clinically characterized by mucocutaneous involvement and classified into erythema multiforme minor and erythema multiforme major (EMM; severe mucosal damage ≥2 mucous coat) (4–6). It is associated with the onset of early systemic symptoms including fever and mucosal involvement with cutaneous lesions appearing after a few days. Clinical incidences of EM are <1% which mainly affect children and young adults.

However, the pathobiological mechanisms underlying the onset of EM have not been fully elucidated. Infections, medications, immunizations, and autoimmune diseases are regarded as etiological agents for EM. Herpes simplex virus (HSV) is the primary cause of EM, accounting for about 70% of the cases, while Mycoplasma pneumoniae (MP) is considered the second most common etiological agent for EM, especially in children (7, 8). In addition, numerous drugs are associated with EM, especially non-steroidal anti-inflammatory drugs, antibiotics [amoxicillin (9), norfloxacin (10), cephalothin (11), trimethoprim-sulfamethoxazole (12)], and antiepileptics. Barbiturates, phenothiazines, statins, and TNF-α inhibitors, among others are also associated with EM onset (13, 14).

Some severe cutaneous adverse reactions (SCARs) encoded by human leucocyte antigen (HLA) have attracted clinical attention (15). Specific HLA gene alleles have been reported to contribute to the increasingly severe skin reactions such as SJS/TEN and EMM, in particular, severe cutaneous adverse drug reactions (cADRs) (16, 17). For instance, HLA-B^*15:02, HLA-B^*15:11, and HLA-B^*46:01 are potential risk factors for carbamazepine-induced SJS/TEN in Asian population (18, 19). Among Thai patients, HLA-B^*46:01 and HLA-A^*02:07 were found to contribute to the pathogenesis of phenytoin and lamotrigine-related cutaneous reactions, respectively (20, 21). HLA-B^*58:1 is associated to both drug reactions with eosinophilia and systemic symptoms (DRESS) and epidermal necrolysis caused by allopurinol (22). The HLA-DQB1^*03:01 genotype is a common marker in herpes-associated EM (HAEM) (23).

In this case report, a pediatric patient with severe Mycoplasma pneumonia who later developed EMM was described. HLA genotypes of the child and her parents were detected to evaluate the association between EM and HLA alleles.

Case Report

An 8-year-old Asiatic girl from south China with acute bronchopneumonia was admitted to the hospital on June 24th, 2019. She had experienced an 8-day unprovoked fever with axillary temperature peaking at 39.5°C, a 6-day dry cough and pharyngeal congestion. Prior to admission, she had been administered with azithromycin (200 mg, qd) and ibuprofen (7 mg/kg, q6h as recommended) for 3 days without clinical remission. The chest X-ray test demonstrated lower left lobe pneumonia. A day after admission, no rales was heard with a stethoscope. Sporadic miliary rashes with raised target (three concentric rings) were observed on her trunk (Figure 1A). Pulmonary infections with fever, listlessness, high respiratory rate (32/min), and high heart rate (128/min) persisted. One or more ocular symptoms, including swollen eyelids, conjunctival hyperemia, increased secretion, and photophobia accompanied by erosive lesions of lips developed. Blood tests showed elevated C-reactive protein (CRP) (77.2 mg/L [normal: <5 mg/L]) and procalcitonin (PCT) (0.12 ng/mL [normal: <0.05 ng/mL]) levels, increased erythrocyte sedimentation rate (ESR) (59 mm/h [normal: 0–34 mm/h]), and high neutrophil percentage (81.4% [normal: 43–75%]). The serological test for HSV-1 and HSV-2 IgM were negative. Other blood parameters such as white blood cell counts were normal. Two days after admission, progressive erythema with painful blistering and raised typical target lesions with three-concentric rings spread on her chest, back, and limbs (Figure 1B), indicating severe erythema multiforme. Electrocardiogram examination revealed sinus tachycardia. Severe MP evidenced by abnormally elevated MP antibodies (IgG [>300 AU/ml [normal: <24.0]) and IgM (5.01[normal: <0.9 S/CO]), left-lower-lobe pneumonia, pleural effusion, multiple infectious lesions in lungs, and dyspnea (shortness of breath) was subsequently diagnosed. Then, she was transferred to the pediatric intensive care unit (PICU). Azithromycin (10 mg/kg/d) was continuously intravenously administered for 5 days. Gamma globulin (γ-globulin) (1.0 g/kg/d for 2 days) and a steroid infusion (methylprednisolone 120 mg/d for 2 days, 200 mg/d for 3 days, then 40 mg/d for 4 days) were followed by sequential oral prednisone.

FIGURE 1

Figure 1. Dynamic changes of erythema multiforme major in an 8-year-old Chinese girl. (A,B) Initiation (A) and progression (B) of erythema multiforme with painful blistering spread in the chest, back, and limbs of the child. (C–E) Cutaneous erythema was further exacerbated (C,D) and new rashes occurred on her hands and feet (E). (F) Local ulcerations on lips and oral mucosa and systemic rash improved after 4 weeks of treatment. Rashes on the lower extremities and abdomen were scab-free. (G) Pigmentation persisted on her arms and shoulders where erythema multiforme had occurred during the follow-up visit after discharge.

After 3 days of admission, erythema developed progressively and further invaded her feet and perineum, and erosion on the lips and oral mucosa was observed (Figure 1C). The color of existing lesions changed to dark-red hue from red. Meanwhile, bilateral acute purulent conjunctivitis had developed for 3 days, and levofloxacin eye drops were used for treatment. General body temperature levels returned to normal following 3-day treatment and pulmonary infection symptoms were subsequently alleviated. Pulmonary auscultation revealed minor moist rales. However, cutaneous erythema was further exacerbated (Figure 1D) and new rashes occurred on her hands and feet on the 6th day after admission (Figure 1E). Given the possibility of drug-induced EMM, highly-associated medications including azithromycin and ibuprofen were withdrawn on the 7th day of treatment and all unnecessary medications were discontinued. Erythromycin eye ointment and calamine lotion were used for lip, mucosa and skin care. Local ulcerations on lips, oral mucosa and systemic rashes were gradually improved over the following weeks of treatment, with some of them scabbing and desquamating. On the 30th day of therapy, rashes on the upper and lower extremities and abdomen were completely scab-free (Figure 1F). Complete blood count (CBC), electrolyte, liver and kidney functions, myocardial enzyme, CRP, PCT, and urine routines tests were in the normal ranges, and the patient was discharged.

The child was clinically monitored for 18 months through follow-up, and no erythema multiforme was reported. At the sites of erythema multiforme, pigmentation persisted on her arms and shoulders (Figure 1G). Allergic rhinitis and cough were diagnosed at 18 months after discharge. Azithromycin was used at home by self-medication in the absence of medical supervision. Rashes appeared on her trunk at 10 h after receiving azithromycin (orally) and then diminished following azithromycin withdrawn and oral administration of antihistamine (loratadine) according to doctor's advice.

Family History and Pedigree

The pedigree chart of the patient's family is presented in Figure 2. The patient had a history of alopecia areata and developed red skin when sweating. Her mother had erythema eruption caused by recurrent herpes virus on her trunk twice in her childhood, and also suffered urticarial papules, and cutaneous pruritus, and xerodermia. Her father had not suffered any dermatosis. The grandfather had an early bald. It remains unknown whether members of generation I in the pedigree chart had suffered any skin disorders.

FIGURE 2

Figure 2. Pedigree of the three-generation (I–III) patient's family. Squares denote males while circles denotes females. Shadow symbols indicate affected individuals, while open symbols represent unaffected individuals. Diagonal lines are used to show that a person is died. Information regarding HLA genotypes associated with EM is also included in the pedigree. II-2 without a history of EM shows the same haplotypes (HLA-DQB1*03:01) as the patient with EMM (III-2).

Immunogenetic Sequencing

After signing an informed consent, peripheral blood samples (2 mL) were collected from the child and her parents for HLA gene sequencing to determine the association between HLA alleles and EMM. After genomic DNA extracted from peripheral blood cells, the HLA alleles including HLA class I (A, B, C), class II (DQA1, DQB1, DPA1, DPB1, DRB1, DRB3, DRB4, DRB5), and HLA-G were genotyped by polymerase chain reaction and Sanger sequencing-based typing (PCR-SSBT) with Applied Biosystems^®3730 DNA Analyzers. The uTYPE^®HLA Sequencing Software was used to perform the analysis. The sequencing results of the family are shown in Table 1. Twenty HLA genotypes were identified for the patient such as HLA-A ^*02:03, HLA-A ^*02:07, HLA-B ^*15:25, and HLA-B ^*46:01. Some HLA genotypes are reported to be highly-associated with cutaneous adverse reactions including EMM and SJS/TEN (Table 2). The HLA genotypes overlapped between the patient and her parents were marked and mapped into a genetic pedigree (Figure 2).

TABLE 1

Table 1. HLA genotypes of the patient and her parents.

TABLE 2

Table 2. Relevant genotypes-based pharmacogenomics relationships between HLA alleles and cutaneous adverse reactions.

Discussion

EM is an acute mucocutaneous hypersensitivity reaction triggered by various etiological factors (31, 32). Timely recognition and treatment of EM is a major challenge. Due to the similarities and overlaps among EM, SJS and TEN, there are some controversies over the precise classification of these skin disorders (33). It is crucial to distinguish between EM and SJS/TEN and choose different treatment approaches. These various clinical entities are defined by the morphology of the individual lesions and their pattern of distribution (34). SJS or SJS/TEN mainly presents macules or flat atypical target lesions and rapidly evolves as a blistering disorder of the skin and mucosal surfaces (1). Conversely, EM are characterized by predominantly acral target lesions but frequently truncal target lesions in children. Typical target lesions which are raised are only found in patients with EM (34). Additionally, MP-induced rash and mucositis (MIRM) emerged as an entity in 2015, which mostly affects mucous membranes and has minimal or even absent cutaneous involvement (35, 36). MIRM has a milder disease course than EMM and SJS/TEN (8). In our case report, raised typical target lesions, involvement of the trunk and extremities, extensive mucosal involvement (≥2 sites, oral and ocular mucous membranes) and systemic symptoms presented are consistent with the diagnostic criteria of EMM except for the body surface area (BSA) of skin lesions. Although we acknowledge that the extensive body surface area affected in our patient would be more consistent with SJS classification according to the consensus classification of severe blistering skin reactions (34), based on the characteristics reported above and the consultation of a pediatric dermatologist from our hospital, a final diagnosis of EMM was eventually made.

Identification of the etiologic agent for EM is important for its management. The most common causes include infections such as herpes simplex and mycoplasmal infection, medications, and autoimmune conditions (31). HSV-associated EM usually presents classic raised target lesions without mucosal involvement. In this case, the HSV IgM in serum was negative and mucosal involvement was observed, ruling out HSV-associated EM secondary to HSV infection. On the 6th day after admission, MP infection was gradually improved after treatment, however, mucocutaneous eruptions was further exacerbated and new rashes occurred on her hands and feet. It suggests that EM was unlikely induced by MP. Drugs are the second most frequent causes of EM (31). In pediatric patients, antibiotics are responsible for the greatest proportion of adverse reactions in EM (57%) and SJS/TEN (30%) hospitalizations (37). Some of the drugs which the patient had taken before the onset of EM can induce cutaneous adverse drug reactions according to the post-marketing information (13). Azithromycin and ibuprofen were highly suspected to induce EM in this case. However, ibuprofen had been discontinued for 5 days when EM appeared. The patient had taken ibuprofen several times in her childhood due to the fever, but didn't develop any cADRs. It suggests that the causative agent is probably azithromycin rather than ibuprofen. Azithromycin, a potent and well-tolerated semisynthetic macrolide from erythromycin, is the most prescribed antibiotic in China. Macrolide antibiotics have been reported to induce severe hypersensitivity related cutaneous reactions, which are rare ADRs (38–40). Pediatric cases have been found to develop SJS associated with azithromycin and reactivation of HSV infections (41). Additionally, SARS-CoV-2-related EM was also reported in adult and pediatric COVID-19 cases and the persons receiving mRNA COVID-19 vaccines (42–44).

Increased hypersensitive reactions to certain drugs may be correlated to specific HLA antigens (45). Studies have revealed the association between HLA alleles and EM, giving more insight in EM pathogenesis (45, 46). HLA gene sequencing was performed in this case and twenty HLA alleles were identified. All the HLA genotypes in the patient are hereditary and those correlated with SCARs and cADRs are summarized in Table 2. HLA-C^*03:04, HLA-A^*02:07, and HLA-DQB1^*03:03 are associated with cADRs such as SJS/TEN and drug reactions with eosinophilia and systemic symptoms (DRESS) in different populations (15, 18, 21, 28). HLA-DQB1^*03:01 is the most frequent allele in EM patients and highly correlated with herpes-associated EM in a case-control study of the Caucasian population (23). HLA-DQB1^*03:02 and HLA-DQB1^*04:02 alleles have been reported to be associated with recurrent HSV-induced EM involving mucous membranes (47). Based on the sequencing results and the association studies between HLA genotypes and cutaneous adverse reactions, we postulate that HLA-DQB1^*03:01 plays a more important role in EMM than other detected alleles (23, 47). There was a genetic resemblance that was associated with the three-generation (I-III) haplotypes in the patient's family. Notably, HLA-DQB1^*03:02 was noticed based on HLA genotypic differences between the patient and her mother. The patient had no sign of HLA-DQB1^*03:02 but her mother had. The history of erythema eruption caused by recurrent herpes virus was confirmed in her mother during a follow-up visit.

EM therapy depends on etiology, disease severity, clinical manifestations, as well as the development of EM (1). Clinical management of EM includes symptomatic treatment with topical corticosteroids and antihistamines and treatment for the underlying etiology. Systemic corticosteroids have been regularly used to treat acute EM for decades (48, 49), although their roles are unknown. In highly suspicious drug-induced EM cases, rapid identification and withdrawal of the causative drugs are critical to avoid immune reactions worsening. Furthermore, re-exposure to the same drug or exposure to drugs with similar chemical structures which may have a potential of cross-reactivity should be avoided. It is essential to strengthen drug patient education and promote rational use of medicines for pediatric patients.

Conclusions

Pediatric EM is an acute, immune-mediated condition affecting the skin and mucosal surfaces in children. An unexpected erythema in an 8-year-old Chinese girl broke out after azithromycin treatment for MP infection, which later developed to EMM. Clinical symptoms of EMM were improved through suspected drug withdrawal and specific treatments. Drugs and genetic factors may have contributed to the EMM-like symptoms. This is the first case report on an Asiatic azithromycin-induced EMM child positive for HLA-DQB1^*03:01. However, causality between EMM and azithromycin needs to be further elucidated. Whether HLA-DQB^*03:01 plays a role in drug-induced EMM remains unknown due to limited information from a single case. Study involving more pediatric patients will be performed to explore the pathological mechanisms and potential genetic characteristics of drug-induced EMM.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding authors.

Ethics Statement

The studies involving human participants were reviewed and approved by Baoan Women's and Children's Health Hospital ethics committee. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the minor(s)' legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

Author Contributions

YL, JX, and PJ contributed to patient's care and clinical data. XF, YL, JL, QC, and HG analyzed the data and wrote the first draft of the manuscript. XF, HG, and PJ contributed to the final version of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [Grant No. 81603185] and the Natural Science Foundation of Guangdong province [Grant No. 2020A1515011452].

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

cADRs, cutaneous adverse drug reaction; CBC, complete blood count; CRP, C-reactive protein; DRESS, drug reactions with eosinophilia and systemic symptoms; EM, Erythema multiforme; EMM, erythema multiforme major; ESR, erythrocyte sedimentation rate; HAEM, herpes-associated EM; HLA, human leukocyte antigen; HSV, Herpes simplex virus; MP, Mycoplasma pneumonia; PCT, procalcitonin; PICU, pediatric intensive care unit; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrosis; WBC, white blood cell.

References

1. Trayes KP, Love G, Studdiford JS. Erythema multiforme: recognition and management. Am Fam Physician. (2019) 100:82–8.

Google Scholar

2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. (1993) 129:92–6. doi: 10.1001/archderm.129.1.92

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. (2017) 390:1996–2011. doi: 10.1016/S0140-6736(16)30378-6

CrossRef Full Text | Google Scholar

4. Ingen-Housz-Oro S, Ortonne N, Chosidow O. The diagnosis is in the rings. BMJ. (2017) 359:j3817. doi: 10.1136/bmj.j3817

CrossRef Full Text | Google Scholar

5. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. (2002) 138:1019–24. doi: 10.1001/archderm.138.8.1019

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Ramien ML, Bahubeshi A, Lara-Corrales I, Pope E, Levy ML, Nopper AJ, et al. Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria. Br J Dermatol. (2021). doi: 10.1111/bjd.20063

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Siedner-Weintraub Y, Gross I, David A, Reif S, Molho-Pessach V. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol. (2017) 97:489–92. doi: 10.2340/00015555-2569

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. (2015) 72:239–45. doi: 10.1016/j.jaad.2014.06.026

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Peng CZ, How CK. Erythema multiforme following antibiotic therapy for pneumonia. QJM. (2013) 106:585–6. doi: 10.1093/qjmed/hcs104

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Baroni A, Piccolo V, Russo T, Cozzolino D, Mascolo M, Chessa MA. Norfloxacin-induced subacute cutaneous lupus with erythema multiforme-like lesions: the enigma of the Rowell syndrome. J Dtsch Dermatol Ges. (2014) 12:1039–42. doi: 10.1111/ddg.12392

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Munoz D, Del Pozo MD, Audicana M, Fernandez E, Fernandez De Corres LF. Erythema-multiforme-like eruption from antibiotics of 3 different groups. Contact Dermat. (1996) 34:227–8. doi: 10.1111/j.1600-0536.1996.tb02187.x

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy. (1995) 15:428–32.

PubMed Abstract | Google Scholar

13. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. (2018) 54:177–84. doi: 10.1007/s12016-017-8667-7

CrossRef Full Text | Google Scholar

14. Nomura H, Takahashi H, Suzuki S, Kurihara Y, Chubachi S, Kawada I, et al. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol. (2017) 44:818–21. doi: 10.1111/1346-8138.13810

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Sukasem C, Pratoomwun J, Satapornpong P, Klaewsongkram J, Rerkpattanapipat T, Rerknimitr P, et al. Genetic Association of Co-Trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes. Clin Pharmacol Ther. (2020) 108:1078–89. doi: 10.1002/cpt.1915

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Yan S, Chen SA, Zhang W, Yang F, Yang Y, Zhu Q, et al. HLA-A^*02 alleles are associated with tetanus antitoxin-induced exanthematous drug eruptions in Chinese patients. Pharmacogenet Genom. (2016) 26:538–46. doi: 10.1097/FPC.0000000000000248

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Fan WL, Shiao MS, Hui RC, Su SC, Wang CW, Chang YC, et al. HLA Association with drug-induced adverse reactions. J Immunol Res. (2017) 2017:3186328. doi: 10.1155/2017/3186328

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. (2013) 14:1821–31. doi: 10.2217/pgs.13.180

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Wang Q, Sun S, Xie M, Zhao K, Li X, Zhao Z. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis. Epilepsy Res. (2017) 135:19–28. doi: 10.1016/j.eplepsyres.2017.05.015

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Sukasem C, Sririttha S, Tempark T, Klaewsongkram J, Rerkpattanapipat T, Puangpetch A, et al. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population. Pharmacoepidemiol Drug Saf. (2020) 29:565–74. doi: 10.1002/pds.4979

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Koomdee N, Pratoomwun J, Jantararoungtong T, Theeramoke V, Tassaneeyakul W, Klaewsongkram J, et al. Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population. Front Pharmacol. (2017) 8:879. doi: 10.3389/fphar.2017.00879

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Kuijper EC, French LE, Tensen CP, Vermeer MH, Bouwes Bavinck JN. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatol Venereol. (2020) 34:1957–71. doi: 10.1111/jdv.16339

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Khalil I, Lepage V, Douay C, Morin L, Al-Daccak R, Wallach D, et al. HLA DQB1^*0301 allele is involved in the susceptibility to erythema multiforme. J Invest Dermatol. (1991) 97:697–700. doi: 10.1111/1523-1747.ep12484029

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Kinoshita Y, Saeki H. A review of toxic epidermal necrolysis management in Japan. Allergol Int. (2017) 66:36–41. doi: 10.1016/j.alit.2016.06.001

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Chen S-A, Zhang L-R, Yang F-P, Yang L-L, Yang Y, Chen Z-H, et al. HLA-A^*02:07 allele associates with clarithromycin-induced cutaneous adverse drug reactions in Chinese patients. Basic Clin Pharmacol Toxicol. (2018) 123:308–13. doi: 10.1111/bcpt.13011

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Yang F, Xuan J, Chen J, Zhong H, Luo H, Zhou P, et al. HLA-B^*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. (2016) 16:83–7. doi: 10.1038/tpj.2015.25

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Jun I, Rim JH, Kim MK, Yoon K-C, Joo C-K, Kinoshita S, et al. Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. Br J Ophthalmol. (2019) 103:573–6. doi: 10.1136/bjophthalmol-2018-313263

PubMed Abstract | CrossRef Full Text | Google Scholar

28. He X-J, Jian L-Y, He X-L, Wu Y, Xu Y-Y, Sun X-J, et al. Association between the HLA-B^*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. Pharmacol Rep. (2013) 65:1256–62. doi: 10.1016/S1734-1140(13)71483-X

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Nakkam N, Konyoung P, Kanjanawart S, Saksit N, Kongpan T, Khaeso K, et al. Pharmacogenetic markers of drug hypersensitivity in a Thai population. Front Genet. (2018) 9:277. doi: 10.3389/fgene.2018.00277

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Ueta M, Nakamura R, Saito Y, Tokunaga K, Sotozono C, Yabe T, et al. Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. Hum Genome Variation. (2019) 6:50. doi: 10.1038/s41439-019-0082-6

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Zoghaib S, Kechichian E, Souaid K, Soutou B, Helou J, Tomb R. Triggers, clinical manifestations, and management of pediatric erythema multiforme: a systematic review. J Am Acad Dermatol. (2019) 81:813–22. doi: 10.1016/j.jaad.2019.02.057

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Heinze A, Tollefson M, Holland KE, Chiu YE. Characteristics of pediatric recurrent erythema multiforme. Pediatr Dermatol. (2018) 35:97–103. doi: 10.1111/pde.13357

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf. (2002) 25:965–72. doi: 10.2165/00002018-200225130-00006

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. J Dtsch Dermatol Ges. (2020) 18:547–53. doi: 10.1111/ddg.14118

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Meyer Sauteur PM, Theiler M, Buettcher M, Seiler M, Weibel L, Berger C. Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia. JAMA Dermatol. (2020) 156:144–50. doi: 10.1001/jamadermatol.2019.3602

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Ramien ML. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol. (2021) 46:420–9. doi: 10.1111/ced.14404

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Sousa-Pinto B, Araújo L, Freitas A, Correia O, Delgado L. Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. Clin Transl Allergy. (2018) 8:2. doi: 10.1186/s13601-017-0188-1

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf. (2009) 18:639–45. doi: 10.1002/pds.1761

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Kamiya K, Nishio E, Horio A, Tokura Y. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol. (2016) 43:340–1. doi: 10.1111/1346-8138.13187

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Pejčić AV. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases. Int J Dermatol. (2021) 60:12–24. doi: 10.1111/ijd.15144

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Aihara Y, Ito S, Kobayashi Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy. (2004) 59:118. doi: 10.1046/j.1398-9995.2003.00336.x

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2. J Eur Acad Dermatol Venereol. (2020) 34:e373–5. doi: 10.1111/jdv.16623

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, et al. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19). J Eur Acad Dermatol Venereol. (2020) 34:e457–9. doi: 10.1111/jdv.16613

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Larenas-Linnemann D, Luna-Pech J, Navarrete-Rodríguez EM, Rodríguez-Pérez N, Arias-Cruz A, Blandón-Vijil MV, et al. Cutaneous manifestations related to COVID-19 immune dysregulation in the pediatric age group. Curr Allergy Asthma Rep. (2021) 21:13. doi: 10.1007/s11882-020-00986-6

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. (2018) 54:147–76. doi: 10.1007/s12016-017-8654-z

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Grassi S, Bossi G, Croci GA, Brazzelli V. Recurrent erythema multiforme major in an 8-year-old patient with recurrence of herpetic gingivostomatitis and HLA-B^*5801 haplotype: a causal or casual relationship? JAAD Case Rep. (2019) 5:617–20. doi: 10.1016/j.jdcr.2019.05.013

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Malo A, Kämpgen E, Wank R. Recurrent herpes simplex virus-induced erythema multiforme: different HLA-DQB1 alleles associate with severe mucous membrane versus skin attacks. Scand J Immunol. (1998) 47:408–11. doi: 10.1046/j.1365-3083.1998.00357.x

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr. (1997) 156:90–3. doi: 10.1007/s004310050561

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. (2009) 2:51–5.

PubMed Abstract | Google Scholar